Article
Hematology
Fadi G. Haddad, Koji Sasaki, Ghayas C. Issa, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia, Jorge Cortes, Marina Konopleva, Naveen Pemmaraju, Yesid Alvarado, Musa Yilmaz, Gautam Borthakur, Courtney DiNardo, Nitin Jain, Naval Daver, Nicholas J. Short, Elias Jabbour, Hagop Kantarjian
Summary: This study evaluated the outcome of TKI discontinuation in CML patients and identified factors associated with success rates of treatment-free remission (TFR). The study found that TFR is safe and feasible in patients with Ph-positive CML on TKI therapy. Achieving MR4 or MR4.5 for at least 5 years was correlated with a better outcome.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Hagop M. Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, John DiPersio, Andreas Hochhaus, Jeffrey Lipton, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael Mauro
Summary: Ponatinib has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia, especially in those resistant to second-generation TKI treatment, and has shown good safety and survival outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
R. Ciftciler, I. C. Haznedaroglu
Summary: Philadelphia (Ph*)/BCR-A BL1-positive chronic myeloid leukemia (CML) is a neoplastic hematologic disorder that can be functionally cured using tyrosine kinase inhibitor (TKI) drugs. Factors such as individual characteristics, drug compliance, lifestyle preferences, comorbidities, and physician experience should be considered when selecting the appropriate first-line TKI for newly diagnosed CML patients.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Medicine, General & Internal
Ik-Chan Song, Sang-Noon Yeon, Myeong-Won Lee, Hyewon Ryu, Hyo-Jin Lee, Hwan-Jung Yun, Byung Joo Sun, Jae-Hyeong Park, Jin-Ok Jeong, Deog-Yeon Jo
Summary: This study retrospectively analyzed the prevalence of pulmonary hypertension (PH) among Korean chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, imatinib, and nilotinib. The results showed that not only dasatinib, but also imatinib and nilotinib could induce PH in CML patients. Risk factors for developing PH included age over 60, dasatinib treatment, and positive cardiopulmonary symptoms/signs at the time of transthoracic echocardiography.
Article
Mathematical & Computational Biology
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Summary: This study successfully classified CML patients with different nilotinib responses by using a dynamical model and laboratory findings. A method was proposed to identify patients who failed to achieve a treatment goal based on data collected at three initial time points only.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS
(2022)
Review
Oncology
Kota Yoshifuji, Koji Sasaki
Summary: The prognosis of CML-CP has significantly improved with the introduction of imatinib. Besides imatinib, other TKIs and a novel drug asciminib are now available. Long-term TKI therapy requires individualized selection based on toxicity profile to minimize chronic toxicity and the risk of adverse events. This review summarizes the characteristics and adverse event profile of each TKI and discusses future perspectives in the treatment of CML-CP.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Massimo Breccia
Summary: The use of TKI in CML patients has brought significant changes to treatment strategies. TKI dose modifications have various applications in different scenarios, aiming not only to improve patient's quality of life but also to achieve and maintain treatment responses.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Peter Remenyi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kroeger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha
Summary: With the introduction of TKI, the number of allo-HCT for CP CML patients has decreased significantly. The use of 1, 2, or 3 TKI prior to allo-HCT does not affect the overall survival, progression-free survival, relapse incidence, or non-relapse mortality. However, the disease stage and KPS score significantly influence the survival and progression-free survival, emphasizing the importance of careful candidate selection and performing allo-HCT during CP1 phase.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Oncology
Sherrie Mikhaeel, Ehab Atallah
Summary: Tyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR), is an important goal in the therapy of chronic myeloid leukemia (CML) due to the impact of TKI therapy on quality of life, long-term side effects, and financial burden. TKI discontinuation is particularly crucial for young CML patients as it affects their growth and development. Multiple studies have demonstrated the safety and feasibility of attempting TKI discontinuation in patients with sustained deep molecular remission.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Biochemistry & Molecular Biology
Yi-Hue Kuo, Shih-Hsiang Wei, Jie-Hau Jiang, Yueh-Shih Chang, Mei-Yin Liu, Shu-Ling Fu, Chi-Ying F. Huang, Wey-Jinq Lin
Summary: This study demonstrates that the deficiency of p38 alpha can enhance the therapeutic efficacy of TKIs on CML cells, while p38 beta deficiency has opposite effects. Specific inhibitors targeting p38 alpha also show potential in enhancing the therapeutic efficacy of TKIs, providing feasibility for future clinical applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Economics
B. Muresan, C. Mamolo, J. C. Cappelleri, M. J. Postma, B. Heeg
Summary: The study found that compared with dasatinib and nilotinib, bosutinib may represent good value for money in treating 2L CP-CML patients.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2021)
Article
Medicine, Research & Experimental
Jani Huuhtanen, Mette Ilander, Bhagwan Yadav, Olli M. J. Dufva, Hanna Lahteenmaki, Tiina Kasanen, Jay Klievink, Ulla Olsson-Stromberg, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Hoglund, Stina Soderlund, Arta Dreimane, Kimmo Porkka, Tobias Gedde-Dahl, Bjorn T. Gjertsen, Leif Stenke, Kristina Myhr-Eriksson, Berit Markevarn, Anna Lubking, Andreja Dimitrijevic, Lene Udby, Ole Weis Bjerrum, Henrik Hjorth-Hansen, Satu Mustjoki
Summary: In patients with chronic myeloid leukemia, combination therapy with dasatinib and IFN-alpha can improve deep molecular remission and restore immune function.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Oncology
Takaaki Ono
Summary: This review discusses the importance of selecting the optimal BCR-ABL1 tyrosine kinase inhibitors (TKIs) for newly diagnosed CML-CP patients, and how individualized treatment choices can be made based on factors such as patient background, treatment goals, and cost.
Article
Multidisciplinary Sciences
Vikalp Kumar Maheshwari, Cassandra Slader, Nidhi Dani, Christina Gkitzia, Quan Yuan, Tengbin Xiong, Yu Liu, Ricardo Viana
Summary: The study found that molecular monitoring in patients with chronic myeloid leukemia in the chronic phase (CML-CP) is cost-effective from a Chinese payer perspective, resulting in increased life years and quality-adjusted life years, as well as cost savings. The key driver of this cost-effectiveness was the opportunity for patients undergoing molecular monitoring to discontinue treatment during treatment-free remission, leading to substantial clinical benefits and cost savings compared to no monitoring. This highlights the importance of investing in molecular monitoring for improved patient outcomes and cost-effectiveness in healthcare systems with limited resources.
Review
Cardiac & Cardiovascular Systems
Sicong Li, Jinshan He, Xinyi Zhang, Yuchun Cai, Jian Liu, Xiaoyan Nie, Luwen Shi
Summary: This study aimed to assess the risk and mechanisms of cardiovascular adverse events in patients treated with nilotinib or imatinib. The results showed that patients treated with nilotinib had a higher risk of cardiovascular adverse events compared to those treated with imatinib. Atherosclerosis caused by inflammation and glycolipid metabolism disorder was identified as the key mechanism of nilotinib cardiotoxicity. Rosuvastatin may be an effective treatment for nilotinib cardiotoxicity.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Hematology
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes
Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.
LANCET HAEMATOLOGY
(2023)
Article
Urology & Nephrology
Camilo Montero, Nancy Yomayusa, Rodolfo Torres, Jorge Cortes, Carlos Alvarez, Juan Gallo, Guillermo Aldana, Andres Acevedo, Maria Rios, Johana Echeverri, Zuly Yepes, Adriana Silva, Diana Gayon, Jorge Perez, Milciades Ibanez
Summary: This study aimed to evaluate asymptomatic CMV reactivation and CMV disease in kidney transplant recipients with positive CMV serostatus. The results showed that asymptomatic CMV reactivation was higher in patients who received thymoglobulin induction, while the rates of CMV disease were similar between the two treatment groups. The significant difference in asymptomatic CMV reactivation between the two groups did not affect graft function and histology.
Article
Oncology
Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe
Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.
Article
Hematology
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K. M. Islam, Jorge Cortes
Summary: Despite advances in cancer outcomes, there are significant health disparities in the treatment of lymphomas. This study examined the representation of different demographic groups in randomized controlled trials (RCTs) for lymphoma and found significant underrepresentation of black, Hispanic, and female patients. Geographic distribution of trials also limited access for patients in certain areas. Correcting enrollment disparities is crucial to ensure that the results of these trials are applicable to all populations.
Article
Oncology
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria Cristina Miggiano, Mario Tiribelli, Massimo Breccia, Luigia Luciano, Valentina Giai, Alessandra Iurlo, Elisabetta Abruzzese, Carmen Fava, Shira Dinner, Jessica K. Altman, Gianantonio Rosti, Jorge Cortes, Marco Vignetti, David Cella
Summary: Patient-reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates. The current findings suggest that systematic monitoring of patient-reported symptoms is associated with high adherence rates.
Article
Oncology
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, Koichi Takahashi, Courtney Dinardo, Guillermo Montalban Bravo, Ghayas C. Issa, Sherry A. Pierce, Kelly A. Soltysiak, Martha S. Tingen, Jorge E. Cortes
Summary: This study investigated the impact of geographic disparities on cancer survival. The study found that factors such as age, income, race, and distance to cancer centers were predictive of survival. The results showed significant disparities in cancer care based on geographic locations.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Virology
Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K. Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, Drew Fransoso, Christina Sun, Tyler Day, Comfort Prah, Trinh Vuong, Patty Ray, Danielle Bradshaw, Marisol Miranda Galvis, Sadanand Fulzele, Girindra Raval, Justin Xavier Moore, Jorge Cortes, Jeffrey N. James, Vamsi Kota, Ravindra Kolhe
Summary: This study aimed to investigate the temporal changes in the humoral immune response among healthcare workers in Augusta, GA, USA, and explore any associations with ethno-demographic features. The findings showed a significant decline in neutralizing antibody (NAb) and IgG levels at 8-12 months post-vaccination, with a more pronounced decline in White HCWs. Booster doses were found to increase antibody levels significantly, while participants without booster doses experienced a decline in antibody levels at 12 months post-vaccination.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Hematology
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
Summary: This article evaluates the impact of social determinants of health on the outcomes of patients with hematologic malignancies. The study found that factors such as education level, health insurance coverage, income level, and marital status significantly affect patients' survival rates. However, there are contradictory reports regarding the effect of distance to treatment centers on treatment outcomes. Additionally, data on transportation, debt, diet, and other factors are lacking.
Review
Hematology
Mahesh Swaminathan, Jorge E. E. Cortes
Summary: Gemtuzumab-ozogamicin (GO) is an ADC approved for the treatment of CD33(+) AML. Despite initial recall due to lack of efficacy and hepatotoxicities, subsequent phase 3 studies showed significant survival benefits with lower and fractionated doses of GO in combination with standard chemotherapy. GO at a dose of 6 mg/m(2) was associated with higher grade > 3 hepatotoxicities and VOD compared to 3 mg/m(2). GO has been reapproved in 2017 and is currently being studied for its role in combination therapies and MRD elimination in CD33(+) AML patients.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Gemma Shay, Michael W. Deininger, Tim H. Bruemmendorf, Jeffrey H. Lipton, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Meeting Abstract
Oncology
Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)